Stocks Basic materials BLGO
OTC · Basic materialsBiolargo, Inc. (BLGO)
Biolargo, Inc. brought in $4.1M of revenue over the twelve months to June 30, 2026, down 70.9% from a year earlier. It posted a net loss of $14.5M. At June 30, 2026 it held $2.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch BLGO in 60 secondsWhat Biolargo, Inc. does
Biolargo, Inc. is registered with the SEC under industry code SIC 2800 (Chemicals & Allied Products). Its shares trade on OTC under the ticker BLGO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.8M | -$11.8M | -$0.04 | n/a |
| 2024 | $17.8M | -$2.4M | -$0.01 | n/a |
| 2023 | $12.2M | -$3.5M | -$0.01 | n/a |
| 2022 | $5.9M | -$4.5M | -$0.01 | n/a |
| 2021 | $2.5M | -$7.1M | -$0.02 | n/a |
| 2020 | $2.4M | -$8.4M | -$0.03 | n/a |
Full financial statements: income, balance sheet and cash flow
Where BLGO ranks in Basic materials
Latest SEC filings
What Biolargo, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Investor disclosure 8-K/A
- September 11, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 55% to $1.2M versus the same quarter last year; diluted EPS -$0.01 versus -$0.00.
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 66% to $1.1M versus the same quarter last year; diluted EPS -$0.01 versus $0.00.
- May 6, 2026
- May 4, 2026
- April 30, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue fell 56% to $7.8M versus the prior year; diluted EPS -$0.04 versus -$0.01.
- April 17, 2026
- April 17, 2026
- April 9, 2026IPO registration S-1
Insider trades
What the people running Biolargo, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 7, 2026 | Code Kenneth ReayChief Science Officer, Director | Received as pay | 532,567 | $60.4K |
| July 1, 2026 | Calvert Dennis PPresident, Director | Received as pay | 219,914 | $24.9K |
| June 30, 2026 | Calvert Dennis PPresident, Director | Received as pay | 699,569 | $79.4K |
| March 31, 2026 | Code Kenneth ReayChief Science Officer, Director | Received as pay | 69,444 | $11.2K |
Who owns BLGO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 37,466,427 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Code Kenneth ReayChief Science Officer, Director | 26,408,319 |
| Calvert Dennis PPresident, Director | 11,058,108 |
Questions about BLGO
What does Biolargo, Inc. do?
Biolargo, Inc. is registered with the SEC under industry code SIC 2800 (Chemicals & Allied Products). Its shares trade on OTC under the ticker BLGO.
Is Biolargo, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.5M on revenue of $4.1M.
How much revenue does Biolargo, Inc. make?
Over the twelve months to June 30, 2026 Biolargo, Inc. reported revenue of $4.1M. That is 70.9% less than a year earlier.
When did Biolargo, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 14, 2026.
Similar companies
Compare BLGO with
Follow BLGO
Get an email when Biolargo, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BLGO: get an email when it filesWhere the numbers come from
Financial figures are the values Biolargo, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.